January 25, 2021Open Access

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Key Points

Key points are not available for this paper at this time.

Abstract

The POLARIS-02 study demonstrated a manageable safety profile and durable clinical response of toripalimab in patients with chemorefractory metastatic NPC. An early decrease in plasma EBV DNA copy number correlated with favorable response.

Bookmark

View Full Paper

Cite This Study

Wang et al. (Mon,) studied this question.

synapsesocial.com/papers/69da461b0f778bd2e4684a3e https://doi.org/https://doi.org/10.1200/jco.20.02712

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma2015 · 139 citations
2Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).2017 · 56 citations
3EBV infection and persistence in nasopharyngeal epithelial cells2014 · 60 citations
4Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer2018 · 4,371 citations
5Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)2018 · 38 citations

Bookmark

View Full Paper